Senti Biosciences (SNTI) Competitors $2.26 +0.06 (+2.49%) Closing price 03:33 PM EasternExtended Trading$2.26 0.00 (0.00%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. TVGN, BTMD, INBX, DSGN, ESPR, NBTX, MDWD, CRDF, IMAB, and PRQRShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Semper Paratus Acquisition (TVGN), biote (BTMD), Inhibrx Biosciences (INBX), Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Nanobiotix (NBTX), MediWound (MDWD), Cardiff Oncology (CRDF), I-Mab (IMAB), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Its Competitors Semper Paratus Acquisition biote Inhibrx Biosciences Design Therapeutics Esperion Therapeutics Nanobiotix MediWound Cardiff Oncology I-Mab ProQR Therapeutics Semper Paratus Acquisition (NASDAQ:TVGN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Do analysts recommend TVGN or SNTI? Semper Paratus Acquisition presently has a consensus price target of $10.00, suggesting a potential upside of 703.21%. Senti Biosciences has a consensus price target of $8.50, suggesting a potential upside of 275.28%. Given Semper Paratus Acquisition's higher probable upside, equities research analysts plainly believe Semper Paratus Acquisition is more favorable than Senti Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TVGN or SNTI more profitable? Semper Paratus Acquisition's return on equity of 0.00% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Semper Paratus AcquisitionN/A N/A -934.56% Senti Biosciences N/A -177.24%-67.38% Do institutionals & insiders hold more shares of TVGN or SNTI? 25.7% of Senti Biosciences shares are owned by institutional investors. 73.2% of Semper Paratus Acquisition shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor TVGN or SNTI? In the previous week, Semper Paratus Acquisition and Semper Paratus Acquisition both had 3 articles in the media. Semper Paratus Acquisition's average media sentiment score of 0.62 beat Senti Biosciences' score of 0.50 indicating that Semper Paratus Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Semper Paratus Acquisition 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, TVGN or SNTI? Semper Paratus Acquisition has higher earnings, but lower revenue than Senti Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSemper Paratus AcquisitionN/AN/A-$13.73MN/AN/ASenti Biosciences$2.56M23.07-$52.79M-$10.84-0.21 Which has more volatility and risk, TVGN or SNTI? Semper Paratus Acquisition has a beta of -0.73, suggesting that its stock price is 173% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. SummarySemper Paratus Acquisition and Senti Biosciences tied by winning 5 of the 10 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.64M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.2121.5627.4020.04Price / Sales23.07281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book0.437.518.085.67Net Income-$52.79M-$55.05M$3.16B$248.47M7 Day Performance7.35%3.16%2.12%2.90%1 Month Performance-28.10%5.92%4.43%5.75%1 Year Performance-30.31%5.82%35.62%21.36% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences2.7345 of 5 stars$2.27+2.5%$8.50+275.3%-43.3%$57.64M$2.56M-0.214TVGNSemper Paratus Acquisition3.9974 of 5 stars$1.16-3.3%$7.10+512.1%+75.8%$220.67MN/A0.003Gap DownBTMDbiote2.6885 of 5 stars$4.01+1.3%$8.00+99.5%-45.2%$216.65M$197.19M6.57194INBXInhibrx Biosciences1.2517 of 5 stars$14.56-2.5%N/A+16.1%$216.12M$200K0.12166News CoverageDSGNDesign Therapeutics0.3947 of 5 stars$3.90+4.3%$4.00+2.6%+15.0%$212.32MN/A-3.9440ESPREsperion Therapeutics4.1413 of 5 stars$1.04-2.8%$7.00+573.1%-50.9%$212.07M$332.31M-1.30200NBTXNanobiotix1.7002 of 5 stars$4.45-0.5%$8.00+79.8%-7.1%$210.68M-$11.61M0.00100Gap UpMDWDMediWound1.6502 of 5 stars$18.99-0.5%$31.80+67.5%+22.9%$206.32M$20.22M-9.0980News CoverageCRDFCardiff Oncology1.6637 of 5 stars$3.16+1.9%$12.00+279.7%+72.6%$206.23M$680K-3.4320IMABI-Mab3.0797 of 5 stars$2.46-1.6%$5.50+123.6%+44.9%$204.15M$3.89M0.00380News CoverageGap UpPRQRProQR Therapeutics2.1709 of 5 stars$1.95+1.0%$8.00+310.3%+29.5%$203.06M$20.46M-5.57180News Coverage Related Companies and Tools Related Companies Semper Paratus Acquisition Alternatives biote Alternatives Inhibrx Biosciences Alternatives Design Therapeutics Alternatives Esperion Therapeutics Alternatives Nanobiotix Alternatives MediWound Alternatives Cardiff Oncology Alternatives I-Mab Alternatives ProQR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
